CELU CELULARITY INC

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference

FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) --  (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright’s 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024.

H.C. Wainwright 26th Annual Global Investment Conference

Date: Monday, September 9, 2024

Time: 12:30 p.m. ET

Location: Lotte New York Palace Hotel, New York

Speaker: Robert J. Hariri, M.D., Ph.D., Founder, Chairman & CEO

Celularity will also participate in one-on-one investor meetings at the conference. To obtain more information on the conference, or schedule an investor meeting with Dr. Hariri, please contact your H.C. Wainwright representative or KCSA Strategic Communications at .

A replay of this presentation will be available on the Company's website at for at least 90 days following the date of the presentation.

About Celularity 

Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

Carlos Ramirez

Senior Vice President, Celularity Inc.

Raquel Cona / Michaela Fawcett

KCSA Strategic Communications

 / 



EN
05/09/2024

Underlying

CELUCELULARITY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CELULARITY INC

 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Receives $12.2 Million from Sale of New Jersey Net Operatin...

Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of approximately $126.3 Million of its unused New Jersey net operating losses (NOLs) and $1.9 Million of unused New Jersey research and development (R&D) tax credits. The NOLs and R&D tax credits sale was administered through New Jersey’s Technology Business Tax Certificate...

February 10, 2026 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ W...

Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet Oz FLORHAM PARK, N.J., Dec. 26, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today released comm...

December 26, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Announces Closing of Financing Transactions

Celularity Announces Closing of Financing Transactions FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclosed financing transactions with Philip A. Barach, co-founder and former president of DoubleLine Capital LP. At the closing, Celularity received $10.00 million in gross proceeds. The transaction structure provides for the potential availability of up to an additional $2.0 million, subject to...

December 22, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity Reaches Binding Term Sheets on Financing Transactions to Su...

Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision The contemplated financing transactions would provide up to $12 Million in capital to support Celularity’s strategic priorities around longevity and preservation of human performance. FLORHAM PARK, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced that it has entered into two binding term sheets for a senior secured term loan and a secured convert...

December 18, 2025 1 EN
 PRESS RELEASE
Free
CELU CELULARITY INC

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative ...

Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, announced today a strategic partnership with DefEYE, Inc. (“DefEYE”), a newly established ophthalmic product and technology company. Celularity has executed an exclusive license & pricing arrangement with DefEYE on the backend of Celularity’s in-kind investment in DefEYE’s $12MM Series Seed Preferred Equit...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch